Incidence of Undiagnosed A-Fib May Be Substantial

Share this content:
Incidence of Undiagnosed A-Fib May Be Substantial
Incidence of Undiagnosed A-Fib May Be Substantial

MONDAY, Aug. 28, 2017 (HealthDay News) -- Many patients at risk for atrial fibrillation (AF) probably do have the condition but have not been diagnosed, according to a study published online Aug. 26 in JAMA Cardiology to coincide with the European Society of Cardiology Congress 2017, held from Aug. 26 to 30 in Barcelona, Spain.

James Reiffel, M.D., a cardiologist and professor at the Columbia University College of Physicians and Surgeons in New York City, and colleagues recruited 385 patients who did not have a diagnosis of AF. About 90 percent of the participants had symptoms related to AF, such as fatigue, breathing problems, or heart palpitations. Many were 75 or older with other risks, such as heart failure, hypertension, diabetes, prior stroke, coronary artery disease, sleep apnea, or chronic obstructive pulmonary disease.

Patients underwent monitoring for 18 to 30 months using insertable cardiac monitors. The researchers found the odds of detecting undiagnosed AF increased the longer patients were monitored. By 30 months, it had been detected in two out of five patients. However, only 13 patients had AF episodes that lasted more than 24 hours (10.2 percent). The researchers noted that oral anticoagulation therapy was prescribed for 72 patients (56.3 percent).

"AF would have gone undetected in most patients had monitoring been limited to 30 days," the authors write. "Further trials regarding the value of detecting subclinical AF and of prophylactic therapies are warranted."

The monitors were provided by Medtronic, which sponsored the study.

Abstract/Full Text
Editorial
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »